Drug Profile
Research programme: small molecule therapeutics - Philogen/Boehringer Ingelheim
Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Philogen
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for research development in Unspecified in Germany
- 28 Aug 2021 No recent reports of development identified for research development in Unspecified in Italy
- 20 Jul 2017 Philogen and Boehringer Ingelheim enter into a collaboration and license agreement to develop small molecule therapeutics